QUICK ANSWERS / LAW.04
Fifteen questions that come up over and over
Cited answers to the questions readers actually ask about CJC-1295's legal status. Informational, not legal advice.
Is CJC-1295 legal in the United States?
There is no single yes-or-no answer, because legal depends on what activity is being asked about and under which body of law. CJC-1295 has never been approved by FDA for any human indication and is therefore an unapproved new drug under 21 U.S.C. § 355(a) when introduced into interstate commerce for human use [15]. It is not on the 503A bulks list, foreclosing traditional pharmacy compounding [13]. It cannot be marketed as a dietary supplement because of the DSHEA exclusion in 21 U.S.C. § 321(ff)(3)(B) [19]. It is not a DEA-scheduled controlled substance — possession is not a CSA offense [17]. Imports may be detained under FDCA Section 801(a) [18]. WADA-tested athletes face strict-liability anti-doping violations [11]. Service members face Department of Defense supplement-policy consequences [20]. Legal in this context is a multi-axis question; the right answer requires naming the axis.
Is CJC-1295 a controlled substance under the DEA schedules?
No. CJC-1295 is not scheduled in any of the five DEA schedules (I through V) under the Controlled Substances Act, 21 U.S.C. §§ 801 et seq. Neither growth hormone itself nor GHRH analogs appear in the federal controlled-substance schedules. Possession of CJC-1295 does not constitute a CSA offense [17]. The lead federal enforcement agency for CJC-1295 is FDA, not DEA — and FDA's authority runs through the Federal Food, Drug, and Cosmetic Act rather than through the CSA. DEA does have a role in HGH-distribution offenses under 21 U.S.C. § 333(e), but as discussed below, § 333(e)'s definitional reach to GHRH analogs is contested in commentary.
What is the FDA approval status of CJC-1295?
Not approved. CJC-1295 has never been the subject of an approved New Drug Application, Biologics License Application, or Abbreviated New Drug Application. The compound went through Phase 1 PK/PD studies in healthy adults in 2006 [2] and entered a Phase 2 trial in HIV-associated visceral adiposity (NCT00267527) that was terminated in October 2006 after a participant death from acute coronary event approximately two hours after the eleventh weekly dose. Independent review judged the event unrelated to study drug, but the program was halted and never restarted [7]. No subsequent sponsor-funded clinical development has occurred and no NDA has been filed. There is no FDA-approved labeling, no approved indication, and no approved manufacturer.
Has CJC-1295 been added to the 503A bulks list for compounding?
No. On December 4, 2024, the Pharmacy Compounding Advisory Committee voted in agreement with FDA's recommendation against inclusion of any of the five CJC-1295 forms — free base, acetate, DAC free base, DAC acetate, and DAC trifluoroacetate — on the Section 503A bulks list. FDA's briefing cited nonclinical findings of DNA damage in pituitary cells, injection-site inflammation and necrosis, the unresolved cardiac signal from the 2006 trial termination, and unaddressed immunogenicity concerns [13]. Because CJC-1295 is also not a component of any FDA-approved drug product and has no USP/NF monograph, all three statutory pathways to lawful 503A pharmacy compounding are foreclosed.
What did the FDA's December 2024 PCAC meeting decide about CJC-1295?
The Pharmacy Compounding Advisory Committee reviewed five chemically distinct forms of CJC-1295 (free base, acetate, DAC free base, DAC acetate, DAC trifluoroacetate) and voted in alignment with FDA's recommendation against inclusion on the 503A bulks list. The agency's briefing document — Docket FDA-2024-N-4777 — cataloged nonclinical findings of reduced food and water intake, softer stools, decreased activity, vomiting, reduced hemoglobin, increased cholesterol, injection-site inflammation and necrosis, and DNA damage in pituitary cells, and identified the unresolved cardiac signal from the 2006 trial termination plus immunogenicity risk of compounded preparations as additional concerns [13]. The vote followed the nominators' September 2024 withdrawal of the nominations and FDA's removal of the substances from Category 2 of the interim 503A bulks list effective September 27, 2024 [12].
Is CJC-1295 legal to possess for research purposes?
Research use only is a meaningful regulatory category, but FDA's intended-use doctrine treats objective evidence of intended human use as overriding the disclaimer language. Vendor marketing copy, promotional claims, customer-base evidence, and dose-form presentation are all considered. Late-2024 FDA Warning Letters expressly targeted vendors selling CJC-1295 under research use only labeling while promoting human use, and FDA treated those promotional contexts as marketing of an unapproved new drug [15][20]. The narrow lawful zone is a properly conducted bench-science context with documented research use; the harder cases involve preparations sold through channels where the customer base is plainly not academic. State pharmacy boards have separately taken action against clinics and terminal distributors of dangerous drugs dispensing CJC-1295 outside the 503A/503B pathway [20].
Can a compounding pharmacy lawfully make CJC-1295 for a patient?
Under the current state of the 503A bulks list, no. As of the December 4, 2024 PCAC vote, CJC-1295 is not on the 503A bulks list, has no USP/NF monograph, and is not a component of any FDA-approved drug product [13]. Those are the three statutory pathways to lawful 503A pharmacy compounding of a bulk substance; CJC-1295 satisfies none of them. The 503B outsourcing-facility pathway is also closed because CJC-1295 is not on the 503B bulks list. State pharmacy boards have taken summary-suspension and settlement actions against pharmacies dispensing CJC-1295 outside the federal pathway, with Ohio's actions against terminal distributors of dangerous drugs as a representative example [20].
Does 21 U.S.C. § 333(e) — the human growth hormone statute — apply to CJC-1295?
Probably not on its face, and this is a common point of confusion worth correcting carefully. Section 333(e) imposes up to five years imprisonment for knowing distribution of human growth hormone for any non-disease use in humans, and defines human growth hormone as somatrem, somatropin, or an analogue of either of them [16]. Somatrem and somatropin are recombinant GH itself. CJC-1295 is a GHRH analog — it acts upstream of GH, at the pituitary GHRH receptor, prompting endogenous GH release [1][3]. Commentators on the statutory text generally read § 333(e) as covering analogs of GH, not GHRH analogs that prompt GH release. This does not mean CJC-1295 distribution for non-medical human use is unreachable under federal law — the general unapproved-new-drug provisions of 21 U.S.C. §§ 331, 333(a), and 355 reach it [15] — but those are different statutes with different penalty structures.
Is CJC-1295 prohibited under WADA anti-doping rules?
Yes, at all times — in and out of competition. CJC-1295 appears on the 2025 World Anti-Doping Agency Prohibited List under Section S2.2.4 (Growth Hormone Releasing Factors), within Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) [11]. Strict liability applies: an athlete is responsible for any prohibited substance found in their sample regardless of how it got there or whether the athlete intended to use it. Detection methods are validated to picogram-per-milliliter concentrations, and samples may be retained for retrospective analysis for up to ten years [10]. A nano-LC quadrupole/orbitrap mass spectrometry method published in 2024 confirms routine WADA-compliant detection of CJC-1295 and related GHRH synthetic analogs in athlete urine at sub-ng/mL limits [10].
Is CJC-1295 on the NCAA banned-substance list?
Yes. CJC-1295 is covered by the NCAA's banned-substance class Peptide Hormones, Growth Factors, Related Substances and Mimetics [14]. The NCAA's policy holds student-athletes strictly accountable for any substance chemically or pharmacologically related to listed compounds, even if not specifically named — meaning detection of CJC-1295 in an athlete's sample supports a finding of a banned-substance violation regardless of whether CJC-1295 itself appears as a named example. Institutional liability also attaches: schools are responsible for any banned substance in their athletes' samples regardless of intent.
Can CJC-1295 be lawfully sold as a dietary supplement?
No. Under 21 U.S.C. § 321(ff)(3)(B), a synthetic article authorized for investigation as a new drug — where substantial clinical investigations have been instituted and made public — cannot subsequently be marketed as a dietary supplement. Because CJC-1295 was the subject of disclosed Phase 1 (Teichman 2006) and Phase 2 (NCT00267527) clinical trials, it falls squarely within this exclusion [19]. FDA treats supplement-style marketing of CJC-1295 as marketing of an unapproved new drug. This is a structural feature of DSHEA, not a discretionary policy choice — the statute itself excludes the article.
Why does the FDA reject 'for research use only' labeling on CJC-1295?
FDA does not reject the research use only category outright — bench-science research with documented research use is a real and legitimate activity. What FDA rejects is the use of the phrase as a shield over conduct whose objective intended use is human administration. The agency's intended-use doctrine evaluates objective evidence — vendor marketing copy, promotional claims, customer-base composition, dose-form presentation — to determine the actual regulatory status of the product. When that evidence points to human use, the research use only label does not change the product's status as an unapproved new drug [15]. The late-2024 Warning Letter campaign was built around this analysis [15][20].
What FDA enforcement actions target CJC-1295 vendors?
Three categories of action are documented in industry legal analysis. Warning Letters to vendors alleging marketing of an unapproved new drug and a misbranded drug — the late-2024 campaign expressly named peptide vendors selling CJC-1295 among others [15]. Import detentions under FDCA Section 801(a) through Import Alerts 66-41 (unapproved finished drugs) and 99-32 (misbranded drugs), authorizing field staff to detain shipments without physical examination [18]. State-level enforcement by state pharmacy boards against terminal distributors of dangerous drugs and clinics dispensing outside the 503A/503B pathway, with Ohio Board of Pharmacy actions cited as representative [20]. Criminal referrals under the general FDCA provisions are also available; § 333(e) — the HGH-specific statute — is widely read as not reaching GHRH analogs on its face [16].
What is the difference between Category 1, 2, and 3 on the FDA interim 503A bulks list?
FDA's interim policy sorts nominated bulk drug substances into three categories pending the final 503A bulks-list rule. Category 1: substances that FDA has identified as eligible for inclusion on the final list, pending the formal rulemaking — compounding may proceed under interim enforcement discretion. Category 2: substances for which significant safety risks have been identified — compounding is not permitted under interim enforcement discretion. CJC-1295 was placed in Category 2 in 2023. Category 3: substances for which FDA has not yet received sufficient supporting information to make a determination. The nominators of CJC-1295 withdrew the nominations in September 2024 [12], and PCAC subsequently voted against inclusion on the final list in December 2024 [13] — moving CJC-1295 out of the interim categories and into the not on the bulks list outcome under the substantive rule.
Can CJC-1295 be lawfully imported into the United States?
Imports are subject to detention and refusal of admission under FDCA Section 801(a), 21 U.S.C. § 381(a). FDA Import Alerts 66-41 (unapproved finished drugs) and 99-32 (misbranded drugs) authorize field staff to detain CJC-1295 shipments without physical examination [18]. For research use only labels on the shipping documentation do not, on their own, defeat this authority — FDA's intended-use doctrine treats the surrounding evidence (vendor marketing, recipient correspondence, prior shipments) as the determining factor [15]. Personal importation policy historically permits limited quantities of certain unapproved drugs under specific conditions, but FDA guidance treats unapproved peptides generally — and CJC-1295 specifically through the Import Alert framework — as outside that policy.